. 2010 Mar-Apr;2(2):137–147. doi: 10.4161/mabs.2.2.11271

Table 6.

Phase 2 study in psoriasis

NCT00245765 ³⁶,³⁷ Phase 2 trial: Moderate-to-severe psoriasis patients (n = 176)
SC CZP 200 mg (400 mg initial dose) or 400 mg, or placebo every 2 weeks for 12 weeks.
Endpoints at week 12		Placebo (n = 59)	CZP 200 mg (n = 59)	CZP 400 mg (n = 58)
Co-primary	PASI 90	1.7%	39.0% (p < 0.001)	46.6% (p < 0.001)
Co-primary	GES marked improvement	13.5%	80.8%	90.2%
Selected Secondary	DLQI mean change from baseline	0.8	8.3 (p < 0.001)	9.9 (p < 0.001)

SC, subcutaneous; CZP, certolizumab pegol; PASI, Psoriasis Area and Severity Index; GES, Global Evaluation Scale; DLQI, Dermatology Life Quality Index.